Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma

Table 2 Clinical characteristics according to the positivity for programmed death-ligand 1 in the primary tumor and lymph node metastasis

Variables	Primary tumor		P value	Lymph node		P value
	PD-L1(-), n = 44 (%)	PD-L1+, n = 24 (%)		PD-L1(-), n = 51 (%)	PD-L1+, n = 17 (%)
Sex			0.417			0.558
Female	14 (31.8)	10 (41.7)		19 (37.3)	5 (29.4)
Male	30 (68.2)	14 (59.3)		32 (62.7)	12 (70.6)
Age (yr)			0.721			0.127
mean (SD)	60.7 (11.8)	61.7 (12.3)		59.8 (12.4)	64.9 (9.7)
BMI (kg/cm²)			0.717			0.271
mean (SD)	24.3 (5.6)	23.9 (3.9)		24.6 (5.2)	23.0 (4.5)
Hemoglobin (g/dL)			0.008a			0.148
mean (SD)	12.4 (2.1)	10.8 (2.5)		12.1 (2.2)	11.1 (2.7)
Neutrophil-lymphocyte ratio			0.703			0.879
mean (SD)	3.30 (4.43)	3.72 (4.21)		3.39 (4.69)	3.31 (3.08)
CCI			0.974			0.539
CCI 0	31 (70.5)	17 (70.8)		35 (68.6)	13 (76.5)
CCI ≥ 1	13 (29.5)	7 (29.2)		16 (31.4)	4 (23.5)
Tumor site			0.635			0.317
Lower	25 (56.8)	15 (62.5)		32 (62.7)	8 (47.1)
Middle	12 (27.3)	6 (25)		11 (21.6)	7 (41.2)
Upper	4 (9.1)	3 (12.5)		5 (9.8)	2 (11.8)
All	3 (6.8)	0 (0)		3 (5.9)	0 (0)
Type of resection			0.323			0.122
Subtotal	22 (50)	9 (37.5)		26 (51)	5 (29.4)
Total	22 (50)	15 (62.5)		25 (49)	12 (70.6)

^aP < 0.05.

PD-L1: Programmed death-ligand 1; BMI: Body mass index; CCI: Charlson-Deyo Comorbidity Index.